SCHEDULE 13G: State Street Corporation Discloses Passive 4.8% Stake in ADMA Biologics Inc.

State Street Corporation has filed a Schedule 13G, reporting a 4.8% passive beneficial ownership stake in ADMA Biologics Inc. as of March 31, 2025.

Summary

• State Street Corporation reported beneficial ownership of 11,440,778 shares of ADMA Biologics Inc. common stock.
• This ownership represents 4.8% of the total outstanding common stock of ADMA Biologics Inc.
• The filing date for this Schedule 13G was May 9, 2025, with the event date triggering the filing being March 31, 2025.
• State Street Corporation, classified as a parent holding company, holds these shares through various investment adviser subsidiaries, including SSGA Funds Management, Inc. and State Street Global Advisors entities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of ADMA Biologics Inc.

Sentiment

Score: 5

Explanation: This is a factual disclosure of ownership, not a performance report. It is neither inherently positive nor negative for the issuer, but rather a routine regulatory filing.

Positives

• A major financial institution, State Street Corporation, holds a significant stake in ADMA Biologics, indicating its inclusion in various investment portfolios managed by State Street's subsidiaries.
• The passive nature of the investment, as certified by State Street, suggests it is part of routine asset management rather than an activist position, which can be viewed as a stable form of institutional ownership.

Negatives

• The reported ownership of 4.8% is below the 5% threshold, meaning State Street Corporation is not a '5% owner' at the time of this specific filing, which might reduce its direct influence or visibility as a major shareholder compared to a 5%+ stake.

Risks

• The passive nature of State Street Corporation's investment means it is not expected to actively engage with ADMA Biologics' management or strategic direction, potentially limiting external pressure for performance improvements.
• Changes in State Street's broader investment strategies or portfolio rebalancing could lead to adjustments in its stake in ADMA Biologics, which might impact share price volatility.

Future Outlook

NA

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from Elizabeth Schaefer, Senior Vice President, Chief Accounting Officer of State Street Corporation).

Industry Context

This filing is a standard disclosure for large institutional investors like State Street Corporation, which manage significant assets across various companies. It reflects their passive investment holdings in publicly traded companies as part of diversified portfolios or index-tracking strategies, providing transparency on significant ownership stakes.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially offering some stability or validation, though the stake is passive.
• Management: Awareness of a large, passive institutional investor on their shareholder register.

Next Steps

• State Street Corporation will continue to monitor its beneficial ownership in ADMA Biologics Inc. and file updated Schedule 13G or 13D statements as required by SEC regulations if its ownership percentage or investment intent changes.

Key Dates

Keywords

ADMA Biologics, State Street Corporation, Schedule 13G, beneficial ownership, institutional investor, common stock, passive investment, SEC filing